NCT05069714View on ClinicalTrials.gov

One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis.

PHASE3CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Rheumatoid ArthritisAutoimmune DiseasesInfluenzaVaccine Reaction
Interventions
DRUG

MTX-hold

Temporary discontinuation of methotrexate for 1 or 2 weeks

Trial Locations (3)

13620

Seoul National Univ. Bundang Hospital, Seongnam-si

03080

Seoul National University Hospital, Seoul

156-707

SMG-SNU Boramae Medical Center, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT05069714 - One or Two Week Methotrexate Discontinuation on Efficacy of Influenza Vaccination in Rheumatoid Arthritis. | Biotech Hunter | Biotech Hunter